Practice Essentials for Using Immune Checkpoint Inhibitors to Treat Lung Cancer and Melanoma

Ask The Experts: The Evolution of Immune Checkpoint Inhibitors to Treat Lung Cancer and Melanoma

Wednesday, March 25, 2020
1:00 – 2:00 p.m. ET

Register Now Handout
Handout available at least 24 hours before webinar.

Immune checkpoint inhibition continues to evolve as standard therapy for a growing number of solid and hematologic malignancies including melanoma and lung cancer.  This educational activity will discuss the pathophysiology and evolution of immune checkpoint inhibitors and analyze recent survival and toxicity data for managing patients with melanoma and lung cancer. Additionally, identification of biomarkers to optimize immune checkpoint inhibitor selection will be explored.

Learning Objectives

  • Define the pathophysiology of immunotherapy and the evolution of immune checkpoint inhibition.
  • Analyze recent immune checkpoint inhibitor survival and toxicity data and apply to the therapy management of patients with melanoma and lung cancer.
  • Identify established and emerging biomarkers to optimize selection of immune checkpoint regimens for patients with melanoma and lung cancer.
  • Describe interprofessional education strategies for patients and caregivers on the safety and monitoring of immune checkpoint inhibitors.

Target Audience

This activity was planned to meet the educational needs of physicians, pharmacists, physician assistants, and nurse practitioners involved in the treatment of lung cancer and melanoma patients with immunotherapies.

Format
This online activity consists of slide presentations, active learning, and an evaluation. View the system requirements.

Faculty

Christine M. Walko, Pharm.D., BCOP, FCCP, Activity Chair
Associate Member, Department of Individualized Cancer Management
Moffitt Cancer Center
Tampa, Florida

Christine M. Walko, Pharm.D., BCOP, FCCP, is a Personalized Medicine Specialist at the DeBartolo Family Personalized Medicine Institute at the H. Lee Moffitt Cancer Center and is also Associate Professor at the University of South Florida Morsani College of Medicine in Tampa, Florida. She is also the Chair of the Clinical Genomics Action Committee (CGAC) and attending on the Personalized Medicine Clinical Service at H. Lee Moffitt Cancer Center. Dr. Walko received her Doctor of Pharmacy from Duquesne University in Pittsburgh. She completed a pharmacy practice residency at Virginia Commonwealth University Health System/Medical College of Virginia Hospitals in Richmond, Virginia. She also completed a Hematology/Oncology specialty residency at the University of North Carolina (UNC) Hospitals and Clinics and a Hematology/Oncology fellowship at the University of North Carolina School of Pharmacy in Chapel Hill, North Carolina. She is a board certified oncology pharmacist.

She has researched and published extensively in oncology therapy and has presented nationally and internationally on oncology and pharmacogenomics and other topics related to treating patients with cancer.

Shetal Patel, M.D., Ph.D.
Assistant Professor of Medicine
Division of Hematology/Oncology
UNC School of Medicine
Chapel Hill, North Carolina

Shetal A. Patel, M.D., Ph.D., is an Assistant Professor of Medicine, Division of Hematology/Oncology at the University of North Carolina (UNC) School of Medicine in Chapel Hill, North Carolina. Dr. Patel specializes in seeing patients with thoracic and head/neck cancer.

Dr. Patel obtained her M.D. and Ph.D. at the University of Pennsylvania, studying cancer biology for her graduate work. She then completed residency training in Internal Medicine at Brigham and Women's Hospital prior to returning to the University of Pennsylvania for a fellowship in Medical Oncology. She has particular interests in translational research related to immune and targeted therapies, by designing novel treatment trials based on preclinical studies. Dr. Patel is a member of the American Society of Clinical Oncology (ASCO), American Association of Cancer Research and the International Association for the Study of Lung Cancer. Dr. Patel also serves as a Molecular Tumor Board member for the ASCO Targeted Agent Profiling and Utilization Registry.
 

CPE Information

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

 

ACPE #: 0204-0000-20-412-L01-P
Activity Type: Application-based
CE Credits: 1.0 hour
Activity Fee: Free of charge

CME Information

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claim CE Within 60 Days

Claim CE (enter the CE code announced during activity and complete the evaluation).

Verify credit has posted to your ​NABP eProfile account before the 60-day deadline.

After ACPE's 60-day deadline, ASHP will no longer be able to report credits.


Join the Live Broadcast

Register Now

Join the live interactive webinar using your computer or smart device. 

Watch for a confirmation email with additional instructions. 

Get the app and view system requirements